Busulfan

證據等級: L5

預測適應症: 10 個

Busulfan: From Alkylating Chemotherapy Agent to Myelodysplastic Syndrome

One-Sentence Summary

Busulfan is a bifunctional alkylating agent classically used in chemotherapy and, more recently, as a cornerstone of pre-transplant conditioning regimens; this evidence pack does not contain a formally coded "original indication" field, but the underlying mechanistic data describe it as a standard component of allogeneic hematopoietic stem cell transplantation (HSCT) conditioning. The TxGNN model predicts it may be effective for Myelodysplastic Syndrome (MDS), with 50 clinical trials and 20 publications currently supporting this direction — much of which reflects an already-established standard-of-care use rather than a truly novel repurposing signal.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (`original_indications` empty; `original_moa` marked as a data gap). Busulfan is a classical alkylating agent historically used for cytoreductive chemotherapy and as HSCT conditioning.
Predicted New Indication	Myelodysplastic Syndrome (MDS)
TxGNN Prediction Score	99.62%
Evidence Level	L2
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed formal MOA data (DrugBank original_moa) is not available in this evidence pack. Based on the mechanistic rationale that is captured in the pack's repurposing_rationale, busulfan is a bifunctional alkylating agent that crosslinks DNA, producing potent, dose-dependent myelotoxicity. This property has historically been exploited for cytoreductive chemotherapy (classically in chronic myeloid leukemia, prior to the tyrosine-kinase-inhibitor era) and — more centrally to the evidence gathered here — as a standard component of myeloablative or reduced-intensity conditioning regimens prior to allogeneic HSCT, typically combined with fludarabine or cyclophosphamide.

The relationship between busulfan's established pharmacology and the top predicted indication, MDS, is direct rather than speculative: MDS is a clonal hematopoietic stem cell disorder for which allogeneic HSCT is the only potentially curative option, and busulfan-based conditioning is already the clinical standard used to ablate the diseased hematopoietic clone and permit donor stem cell engraftment. As the evidence pack itself notes for this candidate: "this is not a genuinely novel indication but rather a consolidation of evidence for an already-established standard clinical use."

Mechanistically, this cytotoxic/myeloablative action is disease-agnostic with respect to which abnormal hematopoietic clone is being eradicated — which is why the model's next several ranked predictions (refractory cytopenia of childhood, unclassified MDS, 5q- deletion syndrome, aregenerative/severe aplastic anemia) all cluster around the same underlying mechanism: busulfan clearing marrow to enable transplant. A more exploratory signal — busulfan conditioning to enable engraftment of CCR5-modified or gene-edited CD34+ cells in HIV cure strategies (rank 7) — extends the same mechanism to an experimental, non-oncologic context and carries substantially weaker, largely Phase 1 evidence.

Clinical Trial Evidence

(for top-ranked predicted indication: Myelodysplastic Syndrome)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06477549	Phase 2	Recruiting	220	RCT comparing bendamustine vs. ruxolitinib added to fludarabine/busulfan conditioning in haploidentical HSCT; graded A relevance — large, directly on-mechanism.
NCT02250937	Phase 2	Active, not recruiting	116	Randomized study of venetoclax with timed-sequential busulfan/cladribine/fludarabine conditioning in AML and MDS; graded A relevance.
NCT00416598	Phase 2	Completed	546	Large trial of decitabine maintenance after busulfan-containing induction/intensification in AML; graded B (busulfan as background agent).
NCT00454480	Phase 2/3	Completed	2000	Large treatment-development program for older AML and high-risk MDS patients incorporating busulfan-based regimens.
NCT00226512	Phase 3	Withdrawn	203	Multi-institutional RCT of non-myeloablative fludarabine/busulfan conditioning ± anti-lymphocyte antibodies for AML/MDS allo-HSCT.
NCT00002989	Phase 3	Unknown	207	Randomized trial assessing intensification of the conditioning regimen for allo-HSCT in leukemia/MDS with high relapse risk.
NCT00301834	Phase 2	Completed	35	Fludarabine/busulfan/alemtuzumab as reduced-toxicity ablative conditioning for children with marrow failure syndromes or MDS/leukemia.
NCT01177371	Phase 2	Completed	13	High-dose busulfan + cyclophosphamide followed by allogeneic BMT for leukemia, MDS, myeloma, and lymphoma.
NCT00186342	N/A	Completed	120	Busulfan/etoposide/cyclophosphamide conditioning; tolerability/efficacy in acute leukemia and MDS/MPD patients aged 51–60.
NCT02861417	Phase 2	Active, not recruiting	204	Timed-sequential busulfan plus post-transplant cyclophosphamide for allogeneic transplantation in blood cancers.

40 additional trials in the evidence pack were not included above for brevity; most are general hematologic-malignancy/HSCT-conditioning trials in which busulfan is a background regimen component rather than the primary study intervention.

Literature Evidence

(for top-ranked predicted indication: Myelodysplastic Syndrome)

PMID	Year	Type	Journal	Key Findings
35617104	2022	RCT	American Journal of Hematology	Final analysis of a Phase III RCT: treosulfan-based conditioning shows non-inferior/superior event-free survival vs. reduced-intensity busulfan in older AML/MDS patients.
31606445	2020	RCT	The Lancet Haematology	Randomized, non-inferiority Phase 3 trial: treosulfan vs. busulfan+fludarabine conditioning before allo-HSCT in older AML/MDS patients.
36702138	2023	RCT (Phase 3)	The Lancet Haematology	Open-label, multicentre RCT: G-CSF+decitabine+busulfan-cyclophosphamide vs. busulfan-cyclophosphamide conditioning to reduce relapse in MDS/secondary AML.
28380315	2017	RCT (Phase 3)	Journal of Clinical Oncology	Randomized comparison of myeloablative vs. reduced-intensity conditioning (busulfan-containing) for AML/MDS allo-HSCT.
34692485	2021	Meta-analysis of RCTs	Frontiers in Oncology	Reduced-intensity conditioning shows comparable outcomes to myeloablative conditioning for AML/MDS allo-HSCT.
33425740	2020	Systematic Review/Meta-analysis	Frontiers in Oncology	Long-term outcomes of treosulfan- vs. busulfan-based conditioning for MDS and AML before HSCT.
40079242	2025	Review	American Journal of Hematology	Contemporary review of allogeneic HSCT for myelofibrosis and MDS, including conditioning regimen selection.
34489555	2021	Cohort (registry, propensity-matched)	Bone Marrow Transplantation	Nationwide Japanese registry: fludarabine/busulfan vs. busulfan/cyclophosphamide myeloablative conditioning for MDS.
33471943	2021	Cohort	Cancer	Fractionated IV busulfan myeloablative conditioning improves survival in older AML/MDS patients.
37856098	2024	Evidence-based risk review	Pediatric Blood & Cancer	Evidence-based assessment of busulfan exposure and subsequent malignancy risk, relevant to non-malignant/gene-therapy conditioning use.

10 additional publications in the evidence pack (largely retrospective cohorts and case reports on treosulfan/busulfan comparisons and long-term toxicity) were not included above for brevity.

Norway Market Information

Busulfan currently holds no marketing authorizations in the regulatory registry captured by this evidence pack (market_status: not marketed; total_licenses: 0). No product name, dosage form, or approved-indication text is available for extraction from taiwan_regulatory.licenses.

Cytotoxicity

Busulfan meets the antineoplastic/cytotoxic criteria: it is a classical alkylating agent, and the evidence pack's own mechanistic rationale explicitly describes it as inducing "DNA crosslinking leading to myeloablative cytotoxicity."

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (alkylating agent, alkyl sulfonate class)
Myelosuppression Risk	High — busulfan is used specifically for its potent, myeloablative bone-marrow-clearing effect in conditioning regimens; profound and prolonged cytopenias are expected and intended in this context.
Emetogenicity Classification	Moderate to High (typical for IV alkylating agents at myeloablative/conditioning doses; confirm exact category against the package insert)
Monitoring Items	CBC with differential, hepatic function (veno-occlusive disease/SOS risk is a known busulfan-class concern), pulmonary function, and — where used at myeloablative doses — seizure prophylaxis and plasma-level (PK-guided) monitoring
Handling Protection	Yes — standard cytotoxic/hazardous drug handling precautions required for preparation and administration

Safety Considerations

Please refer to the package insert for safety information. (key_warnings, contraindications, and drug-interaction data are all marked as data gaps in this evidence pack; no DDI records were found.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The top predicted indication (MDS) is supported by strong, largely Phase 2–3 evidence (L2), including multiple randomized trials directly comparing busulfan-based conditioning regimens in this population — this is less a "new" repurposing hypothesis and more a data-driven confirmation of busulfan's already-standard role in HSCT conditioning for MDS. Lower-ranked predictions in this pack range from moderately supported (refractory cytopenia of childhood, severe aplastic anemia — L2/L3) to essentially unsupported model artifacts (5q- deletion syndrome, seborrheic keratosis, feline AIDS — L5, no trials or literature), and should not be advanced without dedicated evidence.

To proceed, the following is needed:

Official Taiwan/Norway package insert (PI) warnings and contraindications — currently a blocking data gap (DG001); without this, the candidate cannot formally clear the S1 safety pre-screen despite the strength of efficacy evidence.
Confirmed DrugBank MOA record (DG001/DG002) to replace the inferred mechanistic summary used in this report.
Formal original_indications and licensing data, since none were present in this evidence pack.
Given busulfan already lacks Norway marketing authorization, a market-access/registration pathway assessment before any further clinical positioning work.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.